TME PHARM.CONF.IPO EO 1- (F:0N6A) — Stock Price
TME PHARM.CONF.IPO EO 1- (F:0N6A) is currently trading at €0.10 EUR, up 0.99% today. Over the past 52 weeks, shares have ranged between €0.05 and €0.18. This page tracks TME PHARM.CONF.IPO EO 1-'s live share price on the F exchange, its daily price and volume history, and — where reported — its income statement, balance sheet, cash flow statement, and earnings history. To see how efficiently this company converts equity into cash flow, see 0N6A cash flow conversion.
TME PHARM.CONF.IPO EO 1- (0N6A) Stock Price Chart — Daily History & Trading Volume
The chart below tracks TME PHARM.CONF.IPO EO 1-'s daily closing share price and trading volume on the F exchange over the past year, giving a clear view of recent price momentum and liquidity.
TME PHARM.CONF.IPO EO 1- Income Statement — Revenue, Profit & Earnings by Year
TME PHARM.CONF.IPO EO 1-'s annual income statement shows how revenue converts into profit each fiscal year, including gross profit, operating income, EBITDA, and net income.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total Revenue | €0.00 | €0.00 | €0.00 | €0.00 | €0.00 |
| Cost of Revenue | — | — | — | — | — |
| Gross Profit | — | — | — | — | — |
| Research & Development | €1.36 Million | €2.30 Million | €2.65 Million | €8.15 Million | €10.66 Million |
| SG&A | €1.05 Million | €1.60 Million | €1.48 Million | €1.93 Million | €1.26 Million |
| Total Operating Expenses | €2.86 Million | €5.26 Million | €5.62 Million | €12.00 Million | €13.45 Million |
| Operating Income | €-2.86 Million | €-5.26 Million | €-5.62 Million | €-12.00 Million | €-13.45 Million |
| EBITDA | — | — | — | — | — |
| EBIT | — | — | — | — | — |
| Interest Expense | €1.09 Million | €503.00K | €1.52 Million | €3.40 Million | €1.50 Million |
| Income Before Tax | €-3.29 Million | €-5.72 Million | €-6.73 Million | €-15.13 Million | €-14.45 Million |
| Income Tax Expense | — | — | — | — | — |
| Net Income | €-3.29 Million | €-5.72 Million | €-6.74 Million | €-15.13 Million | €-14.45 Million |
TME PHARM.CONF.IPO EO 1- Balance Sheet — Assets, Liabilities & Shareholder Equity
The balance sheet below summarizes TME PHARM.CONF.IPO EO 1-'s financial position at each fiscal year-end — what it owns (assets), what it owes (liabilities), and the resulting shareholder equity.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total Assets | €2.14 Million | €3.41 Million | €2.49 Million | €5.24 Million | €9.77 Million |
| Total Current Assets | €2.12 Million | €3.36 Million | €2.39 Million | €5.01 Million | €9.69 Million |
| Cash & Equivalents | — | — | — | — | — |
| Short-term Investments | €4.00K | €5.00K | — | — | €28.00K |
| Net Receivables | €2.00K | €0.00 | — | — | — |
| Inventory | — | — | — | — | — |
| Property, Plant & Equipment | — | — | — | — | — |
| Goodwill | — | — | — | — | — |
| Total Liabilities | €3.72 Million | €1.79 Million | €2.79 Million | €6.51 Million | €5.27 Million |
| Total Current Liabilities | €3.72 Million | €1.79 Million | €2.79 Million | €6.45 Million | €5.27 Million |
| Long-term Debt | — | — | — | — | — |
| Net Debt | €376.00K | — | — | — | — |
| Total Stockholder Equity | €-1.58 Million | €1.61 Million | €-294.00K | €-1.27 Million | €4.51 Million |
| Retained Earnings | €-203.38 Million | €-200.09 Million | €-194.37 Million | €-187.63 Million | €-172.50 Million |
TME PHARM.CONF.IPO EO 1- Cash Flow Statement — Operating, Investing & Financing Activities
This cash flow statement breaks down how TME PHARM.CONF.IPO EO 1- generates and spends cash across operating, investing, and financing activities each fiscal year, including free cash flow and capital expenditures.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Cash Flow | €-3.42 Million | €-4.63 Million | €-5.63 Million | €-12.14 Million | €-12.38 Million |
| Capital Expenditures | €0.00 | €16.00K | €19.00K | €21.00K | €14.00K |
| Free Cash Flow | €-3.42 Million | €-4.65 Million | €-5.65 Million | €-12.16 Million | €-12.39 Million |
| Investing Cash Flow | — | — | — | — | — |
| Financing Cash Flow | — | — | — | — | — |
| Dividends Paid | — | — | — | — | — |
| Stock-Based Compensation | €85.00K | €312.00K | €396.00K | €589.00K | €475.00K |
| Depreciation | €8.00K | €78.00K | €144.00K | €92.00K | €66.00K |
| Change in Cash | €-1.23 Million | €1.00 Million | €-2.39 Million | €-4.88 Million | €-897.00K |
TME PHARM.CONF.IPO EO 1- Earnings History — EPS Actual vs. Analyst Estimates
Track TME PHARM.CONF.IPO EO 1-'s quarterly earnings per share (EPS) against Wall Street estimates, along with the earnings surprise percentage for each reporting period.
Earnings history is not currently available for TME PHARM.CONF.IPO EO 1-.